Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 251 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Adult Males Clear all

Conditions: Renal Impairment
Interventions: tolebrutinib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Miami, Florida • Saint Paul, Minnesota • Knoxville, Tennessee

Conditions: Pharmacokinetics
Interventions: Theophylline 300mg, Quinine 648 mg, Theophylline 300 mg; Drug
Lead sponsor: Mutual Pharmaceutical Company, Inc.; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Sleep Deprivation
Interventions: SPD489 20 mg, SPD489 50 mg, SPD489 70 mg, Armodafinil, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 135 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Levetiracetam; Drug
Lead sponsor: Dr. Reddy's Laboratories Limited, India; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003
U.S. locations: 1
States / cities: Neptune City, New Jersey

Conditions: Healthy
Interventions: vepdegestrant, esomeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Adult Male
Interventions: MTX-463, Placebo; Biological · Other
Lead sponsor: Mediar Therapeutics; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Volunteer
Interventions: Genz-682452, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Male Adults, Food Effect in Healthy Volunteers
Interventions: AJ201; Drug
Lead sponsor: AnnJi Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Alzheimer Disease
Interventions: 300 mg [C14] CT1812; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Overactive Bladder
Interventions: solabegron and oxybutynin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Tuberculosis
Interventions: PA-824; Drug
Lead sponsor: Global Alliance for TB Drug Development; Other
Eligibility: 19 Years to 50 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: TRV734; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Chronic Kidney Disease Mineral and Bone Disorder
Interventions: Phosphorus Absorption Test; Other
Lead sponsor: Purdue University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Healthy
Interventions: [14C]-TNP-2092; Drug
Lead sponsor: TenNor Therapeutics Limited; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: ABBV-990, Placebo for ABBV-990; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Grayslake, Illinois

Conditions: Healthy
Interventions: Opevesostat, Prednisone, Fludrocortisone acetate, Itraconazole; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 19 Years to 55 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy
Interventions: PA21 and Furosemide with food, No PA21; Furosemide with food, PA21 with food and Furosemide 2hrs later; Drug
Lead sponsor: Vifor Pharma; Industry
Eligibility: 20 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions: Sporanox, Diclofenac Sodium; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Healthy
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Glendale, California

Conditions: Schizophrenia
Interventions: 14C-SEP-380135; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Conditions: Healthy Male Participants
Interventions: BMS-986322; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Prostatic Neoplasms
Interventions: MK-5684, Prednisone, Fludrocortisone acetate, Diltiazem hydrocholoride; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Gout
Interventions: lesinurad 400 mg, naproxen 250 mg, indomethacin 25 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Diabetes Mellitus, Type 2
Interventions: GSK189075, Bupropion, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.

Drug - Drug Interaction Study Between Quinine Sulfate and Theophylline

Pharmacodynamic Profile of SPD489 in Healthy Adult Males Undergoing a Nocturnal Period of Acute Sleep Loss

Bioavailability Study of Levetiracetam Tablets, 750 mg of Dr. Reddy's Under Fasting Conditions.

A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

A Study to Evaluate the Effect of Food on the Bioavailability of AJ201, and Safety, Tolerability, and Pharmacokinetics of AJ201 in Japanese and White Healthy Male Participants

Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male Subjects

A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

A Study of the Safety, Tolerability, and Absorption, Metabolism, and Excretion of PA-824 in Healthy Adult Male Subjects.

A Pharmacokinetic, Safety and Tolerability Study in Healthy Adult Males

Phosphorus Absorption in Healthy Adults and in Patients With Moderate Chronic Kidney Disease

Absorption, Metabolism, and Excretion Study of [14C]-TNP-2092

Study to Assess Adverse Events and How Oral ABBV-990 Moves Through the Body of Adult Healthy Participants

A Drug-Drug Interaction Study of Itraconazole and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-017)

A Drug-Drug Interaction Study of Furosemide and PA21

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

Effects of Vortioxetine (Lu AA21004) on the Concentrations of Selected Neurotransmitters in Healthy Male Adults

A Study to Detect the Radioactivity of 14C-SEP-380135 in Urine and Feces in Healthy Male Adults

A Study to Evaluate the Drug Levels, Metabolism, and Removal of BMS-986322 in Healthy Adult Male Participants

A Drug-Drug Interaction Study of Diltiazem and MK-5684 in Healthy Adult Male Participants (MK-5684-011)

NSAID Drug Interaction Study

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects